11.83
Schlusskurs vom Vortag:
$11.44
Offen:
$11.68
24-Stunden-Volumen:
443.43K
Relative Volume:
0.61
Marktkapitalisierung:
$355.08M
Einnahmen:
$40.61M
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-11.73
EPS:
-1.0081
Netto-Cashflow:
$-26.70M
1W Leistung:
+6.07%
1M Leistung:
+0.58%
6M Leistung:
-17.95%
1J Leistung:
-0.35%
Clearpoint Neuro Inc Stock (CLPT) Company Profile
Firmenname
Clearpoint Neuro Inc
Sektor
Branche
Telefon
(949) 900-6833
Adresse
120 S. SIERRA AVENUE, SOLANA BEACH, CA
Compare CLPT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
CLPT
Clearpoint Neuro Inc
|
11.84 | 343.08M | 40.61M | -29.07M | -26.70M | -1.0081 |
|
ABT
Abbott Laboratories
|
86.66 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
312.95 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
77.59 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
57.66 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
87.56 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Clearpoint Neuro Inc Stock (CLPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-25 | Fortgesetzt | B. Riley Securities | Buy |
| 2023-10-24 | Eingeleitet | Stifel | Buy |
| 2023-02-16 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-05 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-03-18 | Eingeleitet | Lake Street | Buy |
| 2020-07-17 | Eingeleitet | B. Riley FBR | Buy |
Alle ansehen
Clearpoint Neuro Inc Aktie (CLPT) Neueste Nachrichten
Director Matthew Klein of ClearPoint Neuro (CLPT) receives 12,417 shares from RSU vesting - Stock Titan
Tax sale by ClearPoint (CLPT) director after RSU vesting - Stock Titan
Director at ClearPoint Neuro (NASDAQ: CLPT) gains 12,417 shares via RSU vesting - Stock Titan
ClearPoint Neuro (CLPT) investors approve directors, pay and updated incentive plan - Stock Titan
ClearPoint Neuro (CLPT) director converts 12,417 RSUs into common shares - Stock Titan
ClearPoint Neuro (CLPT) director settles 12,417 RSUs into common stock - Stock Titan
Director Pascal Girin converts 12,417 RSUs into ClearPoint Neuro (CLPT) common shares - Stock Titan
ClearPoint Neuro (CLPT) director converts 12,417 RSUs into common stock holdings - Stock Titan
16,000-share sale by CLPT (NASDAQ: CLPT) from vested restricted plan - Stock Titan
ClearPoint Neuro Earnings Call Signals Growth With Strain - TipRanks
Compared to estimates, ClearPoint Neuro (CLPT) Q1 earnings: A look at key metrics - MSN
[144] ClearPoint Neuro, Inc. SEC Filing - Stock Titan
ClearPoint Neuro Inc (CLPT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth By GuruFocus - Investing.com Canada
Clearpoint Neuro, Valneva, Rocket Lab and other big stocks moving lower in Wednesday's pre-market session - MSN
Avoiding Lag: Real-Time Signals in (CLPT) Movement - Stock Traders Daily
ClearPoint Neuro stock (US18507C1099): MAK Capital discloses 6.3% passive stake in CLPT - AD HOC NEWS
MAK Capital reports 6.3% stake in ClearPoint Neuro (CLPT) via Schedule 13G/A - Stock Titan
ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint - ACCESS Newswire
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q1 2026 Earnings Call Transcript - Insider Monkey
Stifel reiterates Clearpoint Neuro stock Buy rating after Q1 beat - Investing.com UK
Stifel Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Stifel reiterates Clearpoint Neuro stock Buy rating after Q1 beat By Investing.com - Investing.com Nigeria
ClearPoint Neuro stock (US18507C1099): Q1 revenue surges 43% to $12.1M - AD HOC NEWS
ClearPoint Neuro Inc.Common Stock (NQ: CLPT - FinancialContent
ClearPoint Neuro, Inc. Q1 2026 earnings preview - MSN
ClearPoint Neuro (CLPT) Reports Record Q1 Revenue of $12.1 Milli - GuruFocus
ClearPoint Neuro Secures CE Marking for Surgical Drill System - Moomoo
ClearPoint forecasts $52m-$56m 2026 revenue range as IRRAflow could be cash neutral as early as 2027 - MSN
ClearPoint Neuro surgical drill receives CE Mark approval - Investing.com UK
Is ClearPoint Neuro (CLPT) 14.8% Undervalued After Q1 2026? EPS - GuruFocus
CLPT Targets Reduced Cash Burn Post-IRRAS Acquisition - GuruFocus
ClearPoint Neuro Q1 Earnings Call Highlights - sharewise.com
ClearPoint Neuro, Inc. (CLPT) reports Q1 loss, lags revenue estimates - MSN
ClearPoint Neuro (CLPT) Gains CE Mark for New Surgical Drill Sys - GuruFocus
CLPT Reports Strong Q1 Revenue Growth in Neurosurgery Sector - GuruFocus
ClearPoint Neuro secures CE mark for Velocity Alpha MR surgical drill system to expand global reach - Traders Union
ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Compared to Estimates, ClearPoint Neuro (CLPT) Q1 Earnings: A Look at Key Metrics - sharewise.com
Earnings call transcript: ClearPoint Neuro Q1 2026 results miss forecasts By Investing.com - Investing.com India
Clearpoint Neuro earnings missed by $0.09, revenue fell short of estimates - Investing.com Canada
ClearPoint (CLPT) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings call transcript: ClearPoint Neuro Q1 2026 results miss forecasts - Investing.com
CLPT: Q1 revenue up 43% to $12.1M; 2026 guidance $52–$56M with strong IRRAflow contribution - TradingView
ClearPoint Neuro Q1 2026 Earnings Call Transcript - Yahoo Finance
Finanzdaten der Clearpoint Neuro Inc-Aktie (CLPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):